secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOXYTRAN, INC (BIXT)
CIK:        0001445815
Form:       8-K
Filed at:   2023-08-24T23:59:59+00:00
Accession:  0001493152-23-030051
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioxytran receives FDA clearance to initiate clinical trials for ProLectin-M in COVID-19
--------------------------------------------------------------------------------

- FDA cleared IND No. 153742 for ProLectin-M, an oral galectin antagonist for mild-to-moderate COVID-19.
- ProLectin-M is Bioxytran's first program to enter the clinic; it aims to showcase broad-spectrum antiviral potential.
- Prior phase 2 trial showed 100% PCR-negative by day 7 and 88% by day 3; no viral rebounds.
- Company preparing for Phase 3 to seek regulatory approval of ProLectin-M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1445815/000149315223030051/0001493152-23-030051-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1445815/000149315223030051/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-030051

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer